Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.
In PLOS this week: novel RIG-I-like receptor regulators, approach for identifying adaptive genes, and more.
New research suggests Ebola virus may appear in survivor sperm samples some nine months after disease onset, though sexual transmission appears relatively rare.
A majority of respondents said liquid biopsy is poised to become a widely used tool for assessing cancer mutations within the next one to four years, with NGS-based analysis preferred over other testing modalities.
NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.
The kit targets several mRNA biomarkers and is the first in a series of salivary diagnostic kits the firm plans to develop for early-stage disease diagnostics.
An epigenome-wide association study suggests a phenotype called mantling is caused by reduced methylation across a newly detected transposon known as Karma.
Researchers from Stanford University have developed a nine-gene panel and a composite risk model to determine prognosis in non-small cell lung cancer.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.